Company Reports

West Pharmaceutical Services is the global market leader in primary packaging and delivery components for injectable therapeutics. Primary packaging has direct contact with the drug product and must be manufactured to ensure stability, purity, and sterility of the drug product in accordance with strict regulatory standards. Because of the mission-critical nature of these components, it is important for customers to trust the quality of manufacturing and design. Key product lines include elastomer components such as stoppers, seals, and plungers, Daikyo Crystal Zenith vials made out of polymer instead of glass, and auto-injectors. Injectables include not only older modalities like small-molecule drugs, insulin, and vaccines but also biologics and GLP-1 obesity drugs.

West Pharmaceutical Services is the global market leader in primary packaging and delivery components for injectable therapeutics. Primary packaging has direct contact with the drug product and must be manufactured to ensure stability, purity, and sterility of the drug product in accordance with strict regulatory standards. Because of the mission-critical nature of these components, it is important for customers to trust the quality of manufacturing and design. Key product lines include elastomer components such as stoppers, seals, and plungers, Daikyo Crystal Zenith vials made out of polymer instead of glass, and auto-injectors. Injectables include not only older modalities like small-molecule drugs, insulin, and vaccines but also biologics and GLP-1 obesity drugs.

West reported year-on-year organic revenue growth of 12.7% and adjusted diluted earnings per share growth of 29% for the quarter. Guidance for 2026 was revised upward to 10.5% organic revenue growth and 23% adjusted diluted EPS growth at the midpoints.

West reported organic revenue growth of 15% to start the year and adjusted diluted earnings per share growth of 47% for the quarter. Guidance for 2026 was revised upward to 8% organic revenue growth and 18% adjusted diluted EPS growth at the midpoints. Shares rallied about 13% as of this writing.

West Pharmaceutical Services is the global market leader in primary packaging and delivery components for injectable therapeutics. Primary packaging has direct contact with the drug product and must be manufactured to ensure stability, purity, and sterility of the drug product in accordance with strict regulatory standards. Because of the mission-critical nature of these components, it is important for customers to trust the quality of manufacturing and design. Key product lines include elastomer components such as stoppers, seals, and plungers, Daikyo Crystal Zenith vials made out of polymer instead of glass, and auto-injectors. Injectables include not only older modalities like small-molecule drugs, insulin, and vaccines but also biologics and GLP-1 obesity drugs.

West reported organic revenue growth of 3% and adjusted diluted earnings per share growth of 12% for the fourth quarter. Guidance for 2026 is 6% organic revenue growth and 10% adjusted diluted EPS growth at the midpoint. Shares are down 5% as of this writing.

West reported organic revenue growth of 5% and adjusted diluted earnings per share growth of 6% for the quarter, triggering a share price rally of over 10%. Management revised full-year guidance upward again, and the midpoints now reflect 5.9% revenue growth and 5% adjusted diluted EPS growth.

West Pharmaceutical reported organic revenue growth of 6.8% and adjusted diluted earnings per share growth of 21%. It revised its full-year guidance for revenue and adjusted EPS upward again by 3% and 8%, respectively, based on the midpoint of its ranges.

West reported organic revenue growth of 2% and adjusted diluted earnings per share decline of 7%. Additionally, management revised full-year guidance for revenue and adjusted EPS upward by 2.4% and 2.5%, respectively, using the midpoint of its ranges.

Over the past week, life science shares have experienced significant volatility related to a deepening trade war with China and as broader US tariffs were implemented and then paused for 90 days to allow time for negotiations. A pharmaceutical-specific tariff is also being considered.

West Pharmaceutical Services is the global market leader in primary packaging and delivery components for injectable therapeutics. Primary packaging has direct contact with the drug product and must be manufactured to ensure stability, purity, and sterility of the drug product in accordance with strict regulatory standards. Because of the mission-critical nature of these components, it is important for customers to trust the quality of manufacturing and design. Key product lines include elastomer components such as stoppers, seals, and plungers, Daikyo Crystal Zenith vials made out of polymer instead of glass, and auto-injectors. Injectables include not only older modalities like small-molecule drugs, insulin, and vaccines but also biologics and GLP-1 obesity drugs.

Wide-moat West Pharmaceuticals reported in-line results but provided 2025 guidance that was significantly below our expectations, putting a dent in the company’s recovery story. The disappointing guidance is primarily due to margin dilution from its SmartDose wearable injector and loss of sales of continuous glucose monitoring, or CGM, devices. Shares fell 38% the day after this news, which we think is an overreaction. However, we have cut our fair value estimate to $310 per share from $378 to factor in uncertainty on midterm operating margins. Overall, we think West's long-term growth story is intact and view the selloff as a long-awaited buying opportunity for a high-quality stock that had been trading at full valuations until now.

West Pharmaceutical Services is the global market leader in primary packaging and delivery components for injectable therapeutics. Primary packaging has direct contact with the drug product and must be manufactured to ensure stability, purity, and sterility of the drug product in accordance with strict regulatory standards. Because of the mission-critical nature of these components, it is important for customers to trust the quality of manufacturing and design. Key product lines include elastomer components such as stoppers, seals, and plungers, Daikyo Crystal Zenith vials made out of polymer instead of glass, and auto-injectors. Injectables includes not only older modalities like small molecule drugs, insulin, and vaccines but also biologics and GLP-1 obesity drugs.

West Pharmaceutical Services is the global market leader in primary packaging and delivery components for injectable therapeutics. Primary packaging has direct contact with the drug product and must be manufactured to ensure stability, purity, and sterility of the drug product in accordance with strict regulatory standards. Because of the mission-critical nature of these components, it is important for customers to trust the quality of manufacturing and design. Key product lines include elastomer components such as stoppers, seals, and plungers, Daikyo Crystal Zenith vials made out of polymer instead of glass, and auto-injectors. Injectables includes not only older modalities like small molecule drugs, insulin, and vaccines but also biologics and GLP-1 obesity drugs.

Wide-moat West Pharmaceuticals reported in-line results that support management’s view that it is on the path to recovery. Although the company continues to experience the adverse effects of inventory destocking, the results and management’s guidance suggest that it can soon return to positive annual growth. We are increasing our fair value estimate to $378 per share from $336 due primarily to a more optimistic view of its growth beyond 2028.

Wide-moat West Pharmaceuticals’ second quarter was disappointing. In addition to continued year-on-year declines in revenue for the three months, the company revised its full-year guidance downward due to the ongoing effects of customer destocking. However, we think West's long-term story remains intact including growth drivers of increasing biologics sales, GLP-1 obesity drug sales, and regulatory pressures pushing customers toward higher-quality packaging solutions. We are maintaining our fair value estimate of $336 per share and view the stock as modestly undervalued after the selloff.

Wide-moat West Pharmaceutical’s first quarter was slightly better than we expected, with reported sales and organic sales down only 3% year on year instead of our forecast of a 6%-7% decline. At first glance, we are maintaining our fair value estimate of $336, and shares declined closer to our fair value after earnings. We continue to think the company’s long-term story is attractive and has potential upside, depending on the impact that the GLP-1 obesity drug industry will have on West’s long-term sales.

West’s fourth-quarter earnings were in line with expectations, but 2024 guidance disappointed due to revenue growth forecasts that were about 6-7 percentage points lower than our expectations. However, we believe the headwinds that management highlighted are likely to be transitory. We have also reviewed our thoughts on the company and reaffirm our wide moat rating thanks to its very strong intangibles and switching costs. We have revised our fair value estimate upward to $336 per share from $290 primarily to reflect updated assumptions on long-term growth. After the recent selloff, we view shares as only slightly above our fair value and think the long-term story remains intact, despite the headwinds in 2024.

West Pharmaceutical Services is the global market leader in primary packaging and delivery components for injectable therapeutics. Primary packaging has direct contact with the drug product and must be manufactured to ensure stability, purity, and sterility of the drug product in accordance with strict regulatory standards. Because of the mission-critical nature of these components, it is important for customers to trust the quality of manufacturing and design. Key product lines include elastomer components such as stoppers, seals, and plungers, Daikyo Crystal Zenith vials made out of polymer instead of glass, and auto-injectors. Injectables includes not only older modalities like small molecule drugs, insulin, and vaccines but also biologics and GLP-1 obesity drugs.

Wide-moat West Pharmaceutical reported third-quarter earnings in line with our expectations. Total organic net sales grew 5.7% year over year, signifying the wind-down of COVID-19-related sales declines. Base sales excluding COVID-19 products increased by over 20% organically year over year, but management trimmed net sales guidance for 2023 to reflect the potential impacts of customers' restocking trends in the fourth quarter. We are maintaining our $290 fair value estimate as our top-line forecast was lower than previous guidance. Shares dropped 11% after the earnings release but still look overvalued to us.